AlphaMark Advisors LLC Purchases 361 Shares of Johnson & Johnson (NYSE:JNJ)

AlphaMark Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 26.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,729 shares of the company’s stock after buying an additional 361 shares during the quarter. AlphaMark Advisors LLC’s holdings in Johnson & Johnson were worth $250,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Olstein Capital Management L.P. lifted its holdings in Johnson & Johnson by 6.6% in the 4th quarter. Olstein Capital Management L.P. now owns 65,000 shares of the company’s stock worth $9,400,000 after buying an additional 4,000 shares during the period. Jacksonville Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth about $439,000. Insight Inv LLC lifted its holdings in shares of Johnson & Johnson by 6.4% during the fourth quarter. Insight Inv LLC now owns 11,424 shares of the company’s stock valued at $1,652,000 after purchasing an additional 685 shares during the last quarter. Advocate Group LLC boosted its holdings in Johnson & Johnson by 5.5% in the fourth quarter. Advocate Group LLC now owns 60,953 shares of the company’s stock worth $8,815,000 after acquiring an additional 3,171 shares in the last quarter. Finally, First Bancorp Inc ME grew its position in Johnson & Johnson by 1.1% during the 4th quarter. First Bancorp Inc ME now owns 8,279 shares of the company’s stock valued at $1,197,000 after purchasing an additional 93 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.5 %

JNJ opened at $150.63 on Wednesday. The stock’s 50 day moving average price is $147.81 and its 200-day moving average price is $156.12. The stock has a market cap of $362.65 billion, a price-to-earnings ratio of 22.65, a P/E/G ratio of 2.45 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.29 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.29%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Morgan Stanley cut their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Barclays upped their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Bank of America cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $170.44.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.